The use of the rat in developmental immunotoxicology studies.
The benefits and costs are discussed for the possibility of using pups generated in breeding studies for additional assessments, such as evaluating immunotoxicity. Such an approach is logistically challenging, but not overwhelming.
Chapin
R E
RE
Pfizer Global R&D, Drug Safety Evaluation, Eastern Point Rd., MS 8274-1336, Groton, Connecticut 06340, USA. robert_e_chapin@groton.pfizer.com
D000818:Animals; D001947:Breeding; D003362:Cost-Benefit Analysis; D004195:Disease Models, Animal; D004781:Environmental Exposure / Q000009:adverse effects*; D005260:Female; D015386:Hazardous Substances / Q000633:toxicity*; D007107:Immune System / Q000187:drug effects* / Q000196:embryology / Q000254:growth & development; D008297:Male; D011247:Pregnancy; D051381:Rats; D012098:Reproduction / Q000187:drug effects; D012107:Research Design; D018570:Risk Assessment; D018675:Toxicity Tests / Q000191:economics; D014116:Toxicology / Q000191:economics / Q000379:methods* / Q000592:standards
D015386:Hazardous Substances